Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31231172 | 1.00 | HPGD (0.47) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22625915 | 0.97 | HPGD (0.49) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10068313 | 0.94 | HPGD (0.51) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL225098 | 0.94 | USP2 (0.51) | HPGDUSP2SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL6943029 | 0.88 | HPGD (0.43) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2279068 | 0.88 | HPGD (0.43) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20482260 | 0.88 | HPGD (0.43) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14709701 | 0.85 | HPGD (0.44) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31693670 | 0.84 | USP2 (0.46) | HPGDUSP2SMN1; SMN2EPHX2FFAR3 | |
| SCHEMBL17469418 | 0.84 | USP2 (0.45) | HPGDUSP2SMN1; SMN2EPHX2FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408838-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-08-07 | — | — | EP | disclosed |
| CN-118076599-A | Dioxazines and their use in the treatment of GBA related diseases | 泽拉丹麦有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023053007-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | KEMPHARM DENMARK A/S (DK) | 2023-04-06 | — | — | WO | disclosed |
| EP-2766360-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2017-07-12 | — | — | EP | disclosed |
| US-8815857-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815857-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20130203729-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203729-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| WO-2013025425-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203729-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, GUCY1B1 | HPGD 357/4885USP2 4187/4885SMN1; SMN2 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.